William Mack & Associates’s iShares Biotechnology ETF IBB Stock Holding History

William Mack & Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$88.6K	Buy	+421	New	+$84.5K	0.03%	180

Other funds holding IBB

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.9B AUM 22.61% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $64.4B AUM 36.06% 1-Year Est. Return

William Mack & Associates's IBB Position: Q3 2026 in Review

William Mack & Associates opened a new position in iShares Biotechnology ETF (IBB) in Q3 2026: 421 shares worth $88.6K. The stake represents 0.03% of the portfolio and ranks #180 among its holdings.

907 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

William Mack & Associates held 421 shares of iShares Biotechnology ETF worth $88.6K as of Q3 2026.
iShares Biotechnology ETF was a new William Mack & Associates position in Q3 2026.
iShares Biotechnology ETF made up 0.03% of William Mack & Associates's portfolio in Q3 2026, its #180 holding.
907 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.